Searchable abstracts of presentations at key conferences in endocrinology

ea0044oc1.4 | Early Career Oral Communications | SFEBES2016

The urinary steroid metabolome as a non-invasive tool to stage non-alcoholic fatty liver disease

Moolla Ahmad , Amin Amin , Hughes Bev , Arlt Wiebke , Hassan-Smith Zaki , Armstrong Matt , Newsome Philip , Shah Tahir , Van Gaal Luc , Verrijken An , Francque Sven , Biehl Michael , Tomlinson Jeremy

Introduction: Dysregulation of glucocorticoid (GC) metabolism is implicated in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). The only available treatment for NAFLD is weight loss and the gold standard diagnostic test is liver biopsy, which is invasive and resource intensive. NAFLD ranges from simple steatosis, to inflammation (steatohepatitis/NASH), fibrosis and cirrhosis. It may be regarded as the hepatic manifestation of the metabolic syndrome and is strongl...

ea0044oc4.6 | Adrenal and Steroids | SFEBES2016

Demographics of adrenal incidentaloma – results from an international prospective multi-centre study in 2190 patients

Bancos Irina , Chortis Vasileios , Lang Katharina , Terzolo Massimo , Fassnacht Martin , Quinkler Marcus , Kastelan Darko , Vassiliadi Dimitra , Beuschlein Felix , Ambroziak Urszula , Deeks Jonathan , Arlt Wiebke

Background: Adrenal masses are discovered in 5% of cross-sectional abdominal imaging scans. Work-up aims at exclusion of malignancy and hormone excess. However, estimates of these risks presently derive from retrospective studies only, mostly small and with significant selection bias.Methods: Prospective multi-centre study (2011–2016) in 21 centres (17 countries) of the European Network for the Study of Adrenal Tumours (ENSAT) with consecutive enrol...

ea0041gp173 | Receptors & Signalling | ECE2016

The changing ‘steroid metabolome’ across the spectrum of non-alcoholic fatty liver disease

Moolla Ahmad , Amin Amin , Hughes Bev , Arlt Wiebke , Hassan-Smith Zaki , Armstrong Matt , Newsome Philip , Shah Tahir , Van Gaal Luc , Verrijken An , Francque Sven , Biehl Michael , Tomlinson Jeremy

Introduction: Dysregulated glucocorticoid (GC) metabolism has been implicated in the pathogenesis of non-alcoholic fatty liver disease (NAFLD). NAFLD extends from simple steatosis, to inflammation (steatohepatitis/NASH), fibrosis and consequent cirrhosis. It is often regarded as the hepatic manifestation of the metabolic syndrome and is independently associated with increased liver and cardiovascular mortality. Changes in GC metabolism have thus far been described in small num...

ea0059oc3.6 | Obesity & diabetes | SFEBES2018

5β-reductase (AKR1D1) is a potent regulator of hepatic insulin sensitivity, carbohydrate and lipid metabolism in vitro and in vivo

Nikolaou Nikolaos , Gathercole Laura , Marchand Lea , Althari Sara , Green Charlotte , McNeil Catriona , Harris Shelley , van de Bunt Martijn , Arlt Wiebke , Hodson Leanne , Tomlinson Jeremy

Steroid hormones and BAs are established regulators of metabolic phenotype. 5β-reductase (AKR1D1) is highly expressed in the liver where it inactivates steroid hormones and catalyses a fundamental step in bile acid (BA) synthesis. We have hypothesised that AKR1D1 plays a crucial regulatory role in hepatic metabolic homeostasis. Genetic manipulation of AKR1D1 was performed in human liver HepG2 and Huh7 cells. Expression changes were confirmed by qPCR and western blotting, ...

ea0059oc5.2 | Adrenal | SFEBES2018

Residual adrenal function in autoimmune addison s disease effect of dual therapy with rituximab and depot tetracosactide

Napier Catherine , Gan Earn H , Mitchell Anna L , Gilligan Lorna C , Rees Aled , Moran Carla , Chatterjee Krishna , Vaidya Bijay , Arlt Wiebke , Pearce Simon HS

In patients with autoimmune Addison’s disease (AAD), exogenous glucocorticoid (GC) therapy is an imperfect substitute for physiological GC secretion; patients on long-term steroid replacement have increased morbidity, reduced life expectancy and poorer quality of life. Recent early-phase studieshave demonstrated that some endogenous steroidogenic function – Residual Adrenal Function (RAF) - is maintained at the point of diagnosis in a proportion of AAD patients; this...

ea0059cc6 | Featured Clinical Cases | SFEBES2018

What lies beneath: cutaneous Kaposi’s sarcoma as a first manifestation of ectopic ACTH-dependent Cushing’s syndrome

Tresoldi Alberto S , Elhassan Yasir S , Asia Miriam , Elshafie Mona , Lane Peter , Manolopoulos Konstantinos N , Velangi Shireen S , Watkins Steven , Arlt Wiebke , O'Reilly Michael W

Introduction: Immune dysregulation is a feature of Cushing’s syndrome (CS). We report a case of CS that presented with rapidly developing cutaneous Kaposi’s sarcoma (KS).Case description: A previously well 59-year-old heterosexual man presented with a two-month history of proximal muscle weakness, recurrent mouth ulcers, and purplish skin lesions. He had a background history of hypertension. Skin biopsies were compatible with KS. History of pas...

ea0038oc2.3 | Translational pathophysiology and therapeutics | SFEBES2015

Further advances in diagnosis of adrenal cancer: a high-throughput urinary steroid profiling method using liquid chromatography tandem mass spectrometry (LC-MS/MS)

Taylor Angela , Bancos Irina , Chortis Vasileios , Lang Katharina , O'Neil Donna , Hughes Beverly , Jenkinson Carl , Deeks Jon , Shackleton Cedric , Biehl Michael , Arlt Wiebke

Context: Differentiating adrenocortical adenoma (ACA) from adrenocortical carcinoma (ACC) represents a continuous challenge in patients with (often incidentally discovered) adrenal masses, with unfavorable sensitivities and specificities provided by tumor size, imaging and even histology. We have previously developed urine steroid metabolomics as a tool for the detection of adrenal malignancy employing gas chromatography mass spectrometry (GC-MS) for the detection of 32 distin...

ea0037oc9.2 | Adrenal 2 | ECE2015

Alternative pathway synthesis dominates androgen production in patients with congenital adrenal hyperplasia and is decreased by Chronocort® more than by conventional glucocorticoid therapy

Jones Christopher , Mallappa Ashwini , Reisch Nicole , Hughes Beverley , O'Neil Donna , Krone Nils , Whitaker Martin , Eckland David , Merke Deborah , Ross Richard , Arlt Wiebke

Suppression of excess androgen production poses a considerable clinical challenge in the management of patients with congenital adrenal hyperplasia (CAH). Whilst the major route of androgen synthesis in humans is the classic pathway via androstenedione and testosterone, the relative contribution of the alternative pathway originating from 17-hydroxyprogesterone to androgen excess in CAH has not been defined. Androgen effects of both pathways are elicited in androgen target tis...

ea0037gp.01.05 | Adrenal | ECE2015

Prevention of adrenal crisis in stress (The PACS Study): serum cortisol during elective surgery, acute trauma and sepsis in comparison to ‘stress dose' hydrocortisone administration in adrenal insufficiency

Taylor Angela , Karavitaki Niki , Smith David , Bancos Irina , Foster Mark , Meier Sibylle , O'Neil Donna , Komninos John , Vassiliadi Dimitra , Mowatt Christopher , Lord Janet , Wass John , Arlt Wiebke

Patients with adrenal insufficiency require increased hydrocortisone (HC) replacement doses during surgery, trauma and infection to avoid life-threatening adrenal crisis. However, currently administered HC doses are chosen empirically rather than on rational grounds, with huge variability in administration modes, total dose and dosing intervals. To conclusively determine serum cortisol levels observed under stress conditions, we firstly collected blood samples from healthy con...

ea0037gp.04.02 | Steroids | ECE2015

The modulation of corticosteroid metabolism by hydrocortisone therapy in patients with hypopituitarism increases tissue glucocorticoid exposure

Sherlock Mark , Behan Lucy Ann , Hannon Mark , Alonso Aurora Aragon , Thompson Christopher , Murray Robert , Crabtree Nicola , Hughes Beverly , Arlt Wiebke , Agha Amar , Toogood Andrew , Stewart Paul M

Context: Patients with hypopituitarism have increased morbidity and mortality. There is ongoing debate around the optimum glucocorticoid replacement therapy.Objective: To assess the effect of glucocorticoid replacement in hypopituitarism on corticosteroid metabolism and its impact on body composition.Design and patients: We assessed the urinary corticosteroid metabolite profile (using gas chromatography/mass spectrometry) and body ...